Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2019

View Archived Issues

"Love hormone" causes heartbreak -- literally

Improving Imbruvica

Identification of a novel potent EML4-ALK inhibitor for non-small cell lung carcinoma

Inebilizumab demonstrates safety and efficacy in phase III N-MOmentum study

Batavia Biosciences and University of Tokyo to develop a vector-based vaccine against Nipah virus

AMS-0421, an aptamer targeting VEGF-A for retinal disease

Protagonist Therapeutics presents phase I data for PN-943

Tolimidone leads to significant reduction of HbA1c in phase IIb trial in type 2 diabetes

Angex Pharmaceutical identifies indoleamine 2,3-dioxygenase 1 inhibitors

Advent Pharma discovers fibroblast growth factor receptor 4 inhibitors

New vasopressin V1A and V2 receptor antagonists described by Bayer

Hitgen patents histone deacetylase inhibitors

Beijing Yuezhikangtai Biomedicines discloses AXL and/or c-Met inhibitors

Integrator proteins shown to resist nerve cell regression

Flotillin-1/2 as a novel target in patients with CNS inflammatory conditions

AEA, PEA and OEA as promising novel biomarkers for autism spectrum disorder

Alzheimer's candidate PRI-002 completes phase I testing

Precision BioSciences describes ARCUS gene editing strategy for hepatitis B

Mutation in ROBO1 gene tied to development of CPHD

FDA approves Bavencio with Inlyta for advanced renal cell carcinoma

Sanofi doses first patient in phase IIb study of SAR-442168 for relapsing MS

Encouraging phase I data reported for dAd5GNE anti-cocaine vaccine

Sienna reports biopsy data from phase IIb study of SNA-120 for psoriasis

DSMB recommends continuation of phase II study of SENS-111 in acute unilateral vestibulopathy

Allegro reports promising results from proof-of-concept study of ALG-007 in dry eye disease

Phase III study of abrocitinib in atopic dermatitis meets all coprimary and secondary endpoints